Neumora Therapeutics, Inc.NMRA
Price (close)
$0.70
Market cap
$130.2M
P/E
—
Revenue (TTM)
—
Net income
-$212.7M
Dividend yield
—
1-year total return
-58.6%
Net margin
—
Revenue growth
—
Debt / equity
2.54x
What Neumora Therapeutics, Inc. does.
No business description on file yet.
Revenue and profit, by fiscal year.
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Net income | — | -$130.9M | -$235.9M | -$243.8M | -$236.9M |
| Free cash flow | — | -$115.4M | -$163.4M | — | — |
More on NMRA.
- Neumora Therapeutics, Inc. summary
- Neumora Therapeutics, Inc. financial statements
- Neumora Therapeutics, Inc. key metrics
- Neumora Therapeutics, Inc. health scores and style box
- Neumora Therapeutics, Inc. earnings
- Neumora Therapeutics, Inc. dividends
- Neumora Therapeutics, Inc. valuation
- Neumora Therapeutics, Inc. ownership and insiders
- Neumora Therapeutics, Inc. peers
Figures from Neumora Therapeutics, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.